Questioning the HIV-AIDS Hypothesis: 30 Years of Dissent*
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
What You Should Know About HIV and AIDS
WHAT YOU SHOULD KNOW ABOUT HIV & AIDS WHAT IS AIDS? AIDS is the Acquired Immune Deficiency Syndrome – a serious illness that makes the body unable to fight infection. A person with AIDS is susceptible to certain infections and cancers. When a person with AIDS cannot fight off infections, this person becomes ill. These infections can eventually kill a person with AIDS. WHAT CAUSES AIDS? The human immunodeficiency virus (HIV) causes AIDS. Early diagnosis of HIV infection is important! If you have been told that you have HIV, you should get prompt medical treatment. In many cases, early treatment can enhance a person’s ability to remain healthy as long as possible. Free or reduced cost anonymous and confidential testing with counseling is available at every local health department in Kentucky. After being infected with HIV, it takes between two weeks to three months before the test can detect antibodies to the virus. HOW IS THE HIV VIRUS SPREAD? Sexual contact (oral, anal, or vaginal intercourse) with an infected person when blood, pre-ejaculation fluid, semen, rectal fluids or cervical/vaginal secretions are exchanged. Sharing syringes, needles, cotton, cookers and other drug injecting equipment with someone who is infected. Receiving contaminated blood or blood products (very unlikely now because blood used in transfusions has been tested for HIV antibodies since March 1985). An infected mother passing HIV to her unborn child before or during childbirth, and through breast feeding. Receipt of transplant, tissue/organs, or artificial insemination from an infected donor. Needle stick or other sharps injury in a health care setting involving an infected person. -
International Guidelines on HIV/AIDS and Human Rights 2006 Consolidated Version
International Guidelines on HIV/AIDS and Human Rights 2006 Consolidated Version Second International Consultation on HIV/AIDS and Human Rights Geneva, 23-25 September 1996 Third International Consultation on HIV/AIDS and Human Rights Geneva, 25-26 July 2002 Organized jointly by the Office of the United Nations High Commissioner for Human Rights and the Joint United Nations Programme on HIV/AIDS OFFICE OF THE UNITED NATIONS HIGH COMMISSIONER FOR HUMAN RIGHTS Material contained in this publication may be freely quoted or reprinted, provided credit is given and a copy containing the reprinted material is sent to the Office of the United Nations High Commissioner for Human Rights, CH-1211 Geneva 10, and to UNAIDS, CH-1211 Geneva 27, Switzerland. The designations employed and the presentation of the material in this publication do not imply expression of any opinion whatsoever on the part of the Secretariat of the United Nations or UNAIDS concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Published jointly by the Office of the United Nations High Commissioner for Human Rights and the Joint United Nations Programme on HIV/AIDS. HR/PUB/06/9 UN PUBLICATION Sales No. E.06.XIV.4 ISBN 92-1-154168-9 © Joint United Nations Programme on HIV/AIDS (UNAIDS) 2006. All rights reserved. Publications produced by UNAIDS can be obtained from the UNAIDS Information Centre. Requests for permission to translate UNAIDS publications—whether for sale or for noncommercial distribution—should also be addressed to the Information Centre at the address below, or by fax, at +41 22 791 4187, or e-mail: [email protected]. -
Kate Fitzgerald
In This Issue: 2020 Young Investigator Awardees pg. 3-9 In Memorium page pg. 14-15 New Member Mini-Bios pg. 19-21 Trials of Interferon Lambda pg. 31 Cytokines 2021 Hybrid Meetin pg. 24-27 Signals THE INTERNATIONAL CYTOKINE & INTERFERON SOCIETY + NEWSLETTER APRIL 2021 I VOLUME 9 I NO. 1 A NOTE FROM THE ICIS PRESIDENT Kate Fitzgerald Dear Colleagues, Greetings from the International Cytokine and Interferon Society! I hope you and your family are staying safe during these still challenging times. Thankfully 2020 is behind us now. We have lived through the COVID-19 pandemic, an event that will continue to impact our lives for some time and likely alter how we live in the future. Despite the obvious difficulties of this past year, I can’t help but marvel at the scientific advances that have been made. With everything from COVID-19 testing, to treatments and especially to the rapid pace of vaccine development, we are so better off today than even a few months back. The approval of remarkably effective COVID-19 vaccines now rolling out in the US, Israel, UK, Europe and across the globe, brings light at the end of the tunnel. The work of many of you has helped shape our understanding of the host response to Sars-CoV2 and the ability of this virus to limit antiviral immunity while simultaneously driving a cytokine driven hyperinflammatory response leading to deadly consequences for patients. The knowledge gained from all of your efforts has been put to good use to stem the threat of this deadly virus. -
Discovery of Oncogenes: the Advent of Molecular Cancer Research
COMMENTARY COMMENTARY Discovery of oncogenes: The advent of molecular cancer research Klaus Bister1 structural comparisons of the a and b subunits Institute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck, of biologically cloned viruses, the transforming A-6020 Innsbruck, Austria principle was defined by the remarkably simple equation a − b = x and was later termed src td (for sarcoma). The first biochemical identifi- In their classic paper on the identification of defective ( ) mutant derivatives, they found cation of a cancer gene was achieved, initially the transforming principle of Rous sarcoma that all transforming virus stocks contained in a chicken virus. However, the principal proof virus (RSV) published 1970 in PNAS (1), two classes of RNA subunits, a larger one a b of a physical underpinning of the cancer gene Peter Duesberg at the University of California, ( ) and a smaller one ( ), whereas the non- hypothesis had tremendous impact on a fun- Berkeley, and Peter Vogt, then at the University transforming yet replication-competent mu- damental challenge of medicine, decoding the of Washington, Seattle, drew a seemingly sim- tants contained the smaller b subunits only. a molecular basis of human carcinogenesis. ple yet groundbreaking conclusion. When they Duesberg and Vogt concluded that the larger The genetic and biochemical investiga- analyzed the genomic RNAs of transforming, subunit contained the transforming princi- tions of the chicken tumor virus RSV and the acutely oncogenic RSV and of transformation- ple of RSV. Based on this and on subsequent persistent search for its transforming prin- ciple are a classic paradigm in cellular and molecular cancer research (2, 3). -
2016 Research in Action Awards
TREATMENT ACTION GROUP The Board of Trustees 2016 RESEARCH IN ACTION AWARDS and staff of amfAR, The Foundation Treatment Action Group’s (TAG’s) annual Research in Action Awards honor activists, scientists, philanthropists and creative artists who have made for AIDS Research extraordinary contributions in the fight against AIDS. Tonight’s awards ceremony is a fundraiser to support TAG’s programs and provides a forum for honoring heroes of the epidemic. salute the recipients of the HONOREES LEVI STRAUSS & CO. for advancing human rights and the fight 2016 TAG Research in Action Awards against HIV/AIDS ROSIE PEREZ actor/activist MARGARET RUSSELL award-winning design journalist/editor, Levi Strauss & Co. cultural leader and accomplished advocate for HIV prevention and care BARBARA HUGHES longtime AIDS activist and dedicated Rosie Perez President of TAG’s Board since 1996 HOSTS Margaret Russell JENNA WOLFE lifestyle and fitness expert BRUCE VILANCH comedy writer, songwriter, actor and Emmy ® Barbara Hughes Award winner THURSDAY, NOVEMBER 17, 2016 6PM Cocktails and Hors d’Oeuvres 7PM Awards Presentation SLATE www.amfar.org 54 West 21st Street New York City TAG ad 102716.indd 1 10/27/16 3:17 PM TAG 2016 LIMITED ART EDITION RIAA 2016 CO-CHAIRS SCOTT CAMPBELL Executive Director, Elton John AIDS Foundation DICK DADEY Executive Director, Citizens Union JOY TOMCHIN Founder of Public Square Films, Executive Producer of How to Survive a Plague and the upcoming documentary Sylvia and Marsha RIAA 2016 HONORARY CHAIRS 2014 RIAA honoree ALAN CUMMING and GRANT SHAFFER 2009 RIAA honoree DAVID HYDE PIERCE and BRIAN HARGROVE ROSALIND FOX SOLOMON Animal Landscape, 1979 Archival pigment print | 15 1/2 x 15 1/2 inches | 8-ply mat + granite welded metal frame + uv plexi 23 1/2 x 23 inches | Edition of 15 + 3 AP's | ©Rosalind Fox Solomon, www.rosalindsolomon.com RIAA 2016 COMMITTEE Courtesy of Bruce Silverstein Gallery Joy Episalla, Chair for Projects Plus, Inc. -
CURRICULUM VITAE Updated on Jan 24, 2020
T. Davtyan, Armenia CURRICULUM VITAE Updated on Jan 24, 2020 Surname Davtyan First name(s) Tigran Affiliation and official address Rhea Pharmaceutical Armenia LLC Armenia, 0084, Yerevan Gusan Sherami St., 2 Building (Malatia-Sebastia adm. district) Republic of Armenia Tel.: (+374-) 91 400994, 98-55-96-29 E-mail: [email protected] [email protected] Present Positions: Professor, Chief Scientist Rhea Pharmaceutical Armenia LLC Home address: Michurin str. 5, 23, 375041, Yerevan, Republic of Armenia. Tel: +374 10 55-96-29 Date and Place of birth: 1 December, 1966, Yerevan, Armenia Nationality: Armenian Citizenship: Republic of Armenia Passport ARM, AH0248176, 24 OCT 2006, 009 ID № 1112660259 Marital status: Married, has 2 children, 3 grandchild Education (degrees, dates, universities) 2016 Professor. Field: Biology 2003 Doctor of Biological Sciences (ScD). Field: Molecular Biology 1993 Candidate of Biological Sciences (Ph.D); Field :Genetics and Immunology 1989-1992 Ph.D. student, Laboratory of Genetic Mechanisms of Cell Malignization And Differentiation, Institute of Cytology, St. Petersburg, Russia. 1983-1988 Yerevan State Medical University, Faculty of Pharmacy Specialization (specify) Drug Design and quality control, HIV/AIDS and clinical immunology; Viral infections; immunity and stress resistance; Molecular mechanisms and Genetic regulation of innate immune response; Autoinflammation; 1 T. Davtyan, Armenia Career/Employment (employers, positions and dates) 2011- 2019 Director of Analytical Laboratory of Scientific Centre of Drug and Medical Thechnology Experttise JSC 1999 - 2011 Head of HIV-Clinical Trail Laboratory of the ARMENICUM Research Center, Yerevan, Rep. of Armenia. 1998 - 2006 Consultant on Science, Laboratory of Immunology, The Second Clinical Hospital of the Yerevan State Medical University, Rep. -
HIV an Illusion Toxic Shock
SCIENTIFIC CORRESPONDENCE generated from a linear model could be a and Ho's] data is remarkable", note that vmons per day is not defined or function of both the baseline CD4 level Loveday et al. 8 report the use of a PCR addressed, nor can it be! No one else has and viral loads. Further studies with larg based assay and find only 200 HIV "virion access to either the unapproved drugs or er sample sizes are needed to resolve RNAs" per ml of serum of AIDS patients the branch PCR technology! What is the these discrepancies. - 1,000 times less than Ho and Wei. So benchmark rate for the turnover of CD4 Shenghan Lai, J. Bryan Page, Hong Lai much for the "remarkable concordance". cells in the general population? Departments of Medicine, Peter Duesberg To counter the 42 case studies of Wei et Psychiatry and Epidemiology, Department of Molecular and Cellular al. 1 and Ho et al.2, we at HEAL (Health University of Miami School of Medicine, Biology, University of California, Education AIDS Liason) can provide at Miami, Florida 33136, USA Berkeley, California 94720, USA least 42 people who are western-blot-posi Harvey Bialy tive for 'HIV', have low T4 cells, who are Bio/Technology, New York, not using orthodox procedures, and have HIV an illusion New York 10010, USA been healthy for years! On the other 1. Maddox, J. Nature 373, 189 (1995). hand, we can also provide you with hun SIR - In an editorial' in the 19 January 2. Ho, D.D. et al. Nature 373, 123-126 (1995). -
Download The
AGING AND HIV THOUGHTS ON PrEP FROM the FIRST PERSON CURED of HIV ARE YOU AT RISK FOR ANAL CANCER? POSITIVELY AWARE THE HIV TREATMENT JOURNAL OF TEST POSITIVE AWARE NETWORK JANUARY+FEBRUARY 2015 LEONG-T RM suRVIVORS ARE Not JUST LIVING loNGER, they’RE KICKING TEZ ANDERSON AND MATT SHARP take on AIDS ASS SURVIVOR SYNDROME This page intentionally left blank. ➤ POSITIVELY AWARE [email protected] CORRE CTING A disease and remind us not to focus exclu- know that all the hard work that goes into CONTRADICTION sively on T-cells and antiretrovirals. compiling such a class A magazine is not IN TERMS —CARL STEIN, MHS, PAC, AAHIVS overlooked. May you be blessed. PHYSiciAN ASSISTANT —C HERYL VITELLO R egarding “Can Hepatitis C Be Sexually OWEN MEDICAL GROUP GATESVILLE, TX Transmitted?” in the November+December SAN FRANCISCO, CA StiGMA 2014 issue: On page 28 Andrew Reynolds responds: I am currently incarcerated at Collins the author writes, Correctional Facility in Collins, New York. “We know that Dear Carl and other readers, I want to tell how I was a target of HIV stigma HCV is present in Thank you for the careful (“Have you ever been the target of HIV stigma blood, but there reading and feedback on the or discrimination?” poll, September+October is no evidence article “Can Hepatitis C Be 2014). It started right in my own neighbor- that it is found Sexually Transmitted?” You are hood after I disclosed to someone who I in semen....” On absolutely correct in my contra- thought was a friend. He eventually told some page 29 the author diction on pages 28 and 29. -
Leon Chaitow Protease Inhibitors the Drug-AIDS Hypothesis Leon
CONTINUUM LeonLeon ChaitowChaitow ––holisticholistic healinghealing && AIDSAIDS ProteaseProtease InhibitorsInhibitors ––thethe hypehype fadesfades TheThe Drug-AIDSDrug-AIDS HypothesisHypothesis —what’s—what’s thethe link?link? changing the way we think about aids vol 4 no 5 february/march 1997 UK £3 USA $5 CONTINUUM a magazine by the living for the living vol 4, no 5 why CONTINUUM? focus february/march 1997 Protease Inhibitors The orthodox view on AIDS holds that it is caused by a virus known as HIV that is PIs in Provincetown 8 JOHN LAURITSEN wonders how hope can transmitted through the exchange of body exact such a price fluids. Once infected, a person will remain well for a time, though infectious to others, From Hype to Hesitation 11 before going on to develop AIDS and dying. Recent research has led to serious caution Despite the huge sums of money spent on reports HUW CHRISTIE medical research, there is still no cure, just drug therapies said to slow the progress of the disease, and regular T-cell counts to measure health. features A whole industry has evolved around New Wave in France 13 AIDS, on which many careers and A recent health conference opened doors to businesses depend, but which offers little freedom of treatment hope to those affected. It works on the premise that HIV=AIDS=DEATH. Interview 14 CONTINUUM began as a newsletter Holistic doctor LEON CHAITOW says AIDS is a encouraging those effected to empower complex scenario which natural healing themselves to make care and treatment methods can address choices. As we look further, anomalies in the orthodox view continue to appear. -
HIV Twenty-Eight Years Later: What Is the Truth? Gary Null, Phd December 3, 2012
HIV Twenty-Eight Years Later: What is the Truth? Gary Null, PhD December 3, 2012 In the May 4, 1984 issue of the prestigious journal Science, one of the most important research papers of the last quarter century was published. “Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS” would rapidly become the medical Magna Carta for the entire gold rush to develop diagnostic methods to identify the presence of HIV in human blood and to invent pharmaceutical drugs and vaccines in a global war against AIDS. This paper, along with three others published in the same issue of Science, was written by Dr. Robert Gallo, then head of the Laboratory of Tumor Cell Biology (LTCB) at the National Cancer Institute (NCI) in Bethesda, Maryland, and his lead researcher Dr. Mikulas Popovic. To this day, this article continues to document the most cited research to prove the HIV hypothesis in scientific papers and places like the nation’s Centers of Disease Control (CDC) website. For virologists, molecular biologists and other infectious disease researchers, particularly those tied to the biotechnology and pharmaceutical industries and the national medical and health institutions, the news of Gallo’s discovery was manna rained down from heaven. All research into other possible causes for the AIDS crisis ended abruptly. As soon as the winds shifted away from earlier efforts to find the cause of AIDS —people’s lifestyles, immune suppressing illicit drug use and other health risks and illnesses that adversely affect the body’s immune system — to that of a single new virus, the case was closed. -
Lessons from an HIV Denialist in the Hills of Thailand
Lessons from an HIV denialist in the hills of Thailand Brian Chang Alpert Medical School, Brown University, Providence, RI, USA I spent a month volunteering with Dr. Mark,* a physician in community. Further, denialist movements often go beyond science, the hill tribe villages of northern Thailand, in the summer of 2010. becoming “a social movement in which large numbers of people He was born in Myanmar, graduated from medical school in India come together and propound their views with missionary zeal.”3 and founded a small grassroots organization dedicated to the health HIV/AIDS denialism itself exists in a spectrum, ranging from of hill tribe villagers. He spent the last five years moving from village the rejection of the fact that HIV is a virus, to the denial of the caus- to village along the mountainous Thai-Burmese border, working on ative relationship between HIV and AIDS. I read arguments from sanitation projects and seeing patients in makeshift clinics. He is hard Dr. Peter Duesberg, a prominent cancer researcher, member of the working, humble and is known for his fluency in eight languages, in- National Academy of Sciences and a key voice in denying that HIV cluding all six of the local hill tribe dialects. During my month with causes AIDS. I also read claims from groups like RethinkingAIDS, Dr. Mark and his organization, I helped build toilets, collect water an international group of over 2,500 scientists, doctors and journal- supplies and run medical clinics. ists “reevaluating the HIV/AIDS hypothesis.”4-6 In fact, AIDS de- Through this experience and my discussions about HIV/AIDS nialists (including Dr. -
Nudging Towards Vaccination: a Behavioral Law and Economics Approach to Childhood Immunization Policy*
LASKOWSKI.TOPRINTER (DO NOT DELETE) 2/1/2016 6:52 PM Nudging Towards Vaccination: A Behavioral Law and Economics Approach * to Childhood Immunization Policy I. Introduction The Bill & Melinda Gates Foundation declared this decade “the Decade of Vaccines.”1 Vaccines are more effective and protect against more diseases than ever before;2 yet childhood immunization rates in the United States and many other industrialized nations are declining.3 Diseases that had been declared eradicated in the United States are increasingly reappearing.4 Most recently in early 2015, a large multistate measles outbreak was linked to an infected individual who had visited Disneyland in Southern California. A study concluded that the outbreak was likely a result of substandard vaccination rates.5 The anti-vaccination movement can be traced to a paper published by British doctor Andrew Wakefield in 1998 that claimed there might be a connection between the measles, mumps, and rubella (MMR) vaccine and * I would like to thank Professor Sean H. Williams for his guidance and assistance with early drafts of this Note. I would also like to thank the Texas Law Review staff for all the hard work put into the editing process. Finally, thank you to my parents for their love and support over the years. 1. Vaccine Delivery: Strategy Overview, BILL & MELINDA GATES FOUND., http://www .gatesfoundation.org/What-We-Do/Global-Development/Vaccine-Delivery [http://perma.cc/XQY4-F9GC]. 2. Ensuring Vaccine Safety, CENTERS FOR DISEASE CONTROL & PREVENTION, http://www .cdc.gov/vaccinesafety/ensuringsafety/index.html [http://perma.cc/QWP8-3G3V]; see Vaccine History: Developments by Year, CHILD.